Navigation Links
DioGenix Issued Seminal Patent for Diagnosing Early-stage Neurological Diseases
Date:3/18/2013

GAITHERSBURG, Md., March 18, 2013 /PRNewswire/ -- DioGenix, Inc. announced today that the United States Patent and Trademark Office has issued a patent that broadly protects DioGenix' proprietary next-generation sequencing assay, MSPrecise™, that has shown in recent clinical studies to accurately identify patients with multiple sclerosis (MS) at first clinical presentation.

"This patent, combined with DioGenix' expertise in developing novel molecular tests, is a strategic necessity, as our lead clinical trial advances to validate the accuracy of MSPrecise in real-world populations being evaluated for a variety of neuroimmune diseases like MS. These rights are merely the first in a growing patent estate based on novel insights into human neurology from a series of clinical studies initiated by the combined team at DioGenix and the University of Texas Southwestern Medical Center (UTSW)," said Larry Tiffany , President and CEO of DioGenix. "Indeed, this patent is a cornerstone of our intellectual property portfolio that allows the company to pursue a longer-term strategy; building a comprehensive pipeline of tests for a variety of immune-mediated neurological diseases."

U.S. Patent 8394583 entitled "VH4 Codon Signature for Multiple Sclerosis" claims and describes the use of DNA mutational analysis to profile the immune response of patients suspected of MS across a variety of biosamples (including cerebral spinal fluid and blood) and resulting biomolecules (DNA and RNA).  Specific "hot spots" are identified where the mutational frequency of DNA changes are more prevalent in patients with MS than in other similar neurological diseases and healthy controls.

"As we continue to immunoprofile patients that are difficult to discriminate given indefinite clinical symptoms, we believe that our patented approach will allow DioGenix to develop specific DNA mutational profiles for a host of immune-mediated neurological diseases," Mr. Tiffany continued.   

About MSPrecise
MSPrecise is based on the pioneering work of Dr. Nancy Monson of UTSW now utilizing next-generation sequencing to measure DNA mutations found in rearranged immunoglobin genes in immune cells initially isolated from cerebrospinal fluid. MSPrecise would augment the current standard of care for the diagnosis of MS by providing a more specific measurement of a patient's immune response to a challenge within the central nervous system. This novel method of measuring changes in adaptive human immunity may also be able to discern individuals whose disease is more progressive and requires more aggressive treatment. 

About DioGenix, Inc.
DioGenix is developing novel molecular tests using application-specific, high-resolution state-of-the-art technologies that measure well-established human biology. With a focus in immune-mediated neurological diseases and disorders, DioGenix combines powerful insight into clinical diagnostic pathways with proprietary technology that results in earlier, more personalized intervention and treatment. The company's lead product, MSPrecise™, is currently being evaluated in a prospective trial to evaluate its clinical performance in identifying patients that have, or are at risk of developing multiple sclerosis. DioGenix is based Gaithersburg, MD. For additional information, please visit http://www.diogenix.com.


'/>"/>
SOURCE DioGenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DioGenix and Fast Forward Collaborate to Develop Blood-Based Molecular Diagnostic for Multiple Sclerosis
2. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
3. Southern Home Medical Once Again Reduces The Companys Issued And Outstanding Preferred Shares
4. Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439
5. Organovo Announces Two Issued Patents, First Company Patent and Key Founder Patent
6. NW Bio Receives U.S. Patent On Broad Processes For Producing More Potent Dendritic Cells
7. Medbox Acquires 50% of MedVend and its Patented Technologies
8. In Age of Patent Expiration, Planning Groups for New Pharma Products Growing in Importance
9. OrbusNeich File Patent Infringement Lawsuit Against Boston Scientific in Ireland
10. Amedica Expands Patent Portfolio with Proprietary Silicon Nitride Total Disc Implant to Treat Neck and Back Pain
11. BioElectronics Announces Publication of Patent Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):